OKYO Pharma (OKYO) vs OS Therapies (OSTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OS Therapies (OSTX) has outperformed OKYO Pharma (OKYO) over the past year, losing 20.6% versus a loss of 37.9%. OS Therapies is the larger company by market cap ($75.8 million vs $72.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OKYO | OSTX |
|---|---|---|
| Share price | $1.39 | $1.62 |
| Market cap | $72.95M | $75.82M |
| 1-day change | -2.73% | +4.52% |
| YTD return | -32.85% | +15.71% |
| 1-year return | -37.95% | -20.59% |
| Forward P/E | — | 4.67 |
| EPS (TTM) | $-0.24 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $2.25 |
| 52-week low | $1.27 | $1.15 |
| Distance from 52-week high | -56.56% | -28.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +499.28% | +424.69% |
| Average volume | 94.59K | 586.70K |
| Shares outstanding | 52.48M | 46.81M |
| Employees | 5 | 4 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OSTX has outperformed OKYO by 17.4 percentage points over the past year.
About OKYO Pharma
OKYO stock →OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
Healthcare · Biotechnology · 5 employees
About OS Therapies
OSTX stock →OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Healthcare · Biotechnology · 4 employees
OKYO vs OSTX FAQ
Which is bigger, OKYO Pharma or OS Therapies?
OS Therapies (OSTX) is larger, with a market capitalization of $75.82M compared with $72.95M for OKYO Pharma (OKYO).
Which stock has performed better over the past year, OKYO or OSTX?
OSTX returned -20.59% over the past 12 months, compared with -37.95% for OKYO (price return, excluding dividends). Past performance does not predict future results.
Are OKYO Pharma and OS Therapies in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.